source
- Sellas’ Phase 3 REGAL AML Immunotherapy Study Delayed, Forecast to Miss Survival EndpointSellas Life Sciences Group’s experimental immunotherapy galinpepimut‑S (GPS) is being tested in a Phase 3 REGAL trial for patients with acute myeloid leukemia in a second remission. The study has b…
- Roche partners with Dualitas Therapeutics in up to $1 billion deal to screen bispecific antibodies for immune diseasesRoche has committed $36.5 million up front to biotechnology startup Dualitas Therapeutics under a research partnership that could total up to $1 billion in milestone payments and royalties. The agr…